Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266238 | 0.88 | ALDH1A1 (0.50) | TSHRALDH1A1POLBCYP3A4CYP2C9 | |
| SCHEMBL1619442 | 0.81 | CYP2D6 (0.53) | TSHRCYP2D6USP2KDM4EALDH1A1 | |
| SCHEMBL1619050 | 0.81 | CYP2D6 (0.53) | TSHRCYP2D6USP2KDM4EALDH1A1 | |
| SCHEMBL5241006 | 0.80 | CYP2D6 (0.52) | TSHRCYP2D6USP2KDM4EALDH1A1 | |
| SCHEMBL11835973 | 0.80 | ALDH1A1 (0.52) | KDM4EALDH1A1POLBL3MBTL1TP53 | |
| SCHEMBL4776900 | 0.77 | CYP2C9 (0.47) | ALDH1A1POLBLMNAL3MBTL1TP53 | |
| SCHEMBL5316198 | 0.77 | DRD4 (0.50) | — | |
| SCHEMBL12187772 | 0.76 | FUCA1 (0.55) | CYP2D6ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL60509 | 0.76 | FUCA1 (0.55) | CYP2D6ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL3315165 | 0.76 | FUCA1 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20100160626-A1 | Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| EP-1554285-B1 | CHEMICAL INTERMEDIATE | ASTRAZENECA AB (SE) | 2010-01-13 | — | — | EP | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090240051-A1 | New process for the production of oxabispidines | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| US-20090062532-A1 | Chemical Intermediate | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090036675-A1 | New process for production of oxabispidines | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083690-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083691-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002028863-A1 | NEW OXABISPIDINE COMPOUND USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002028864-A1 | NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | TSHR 948/4885CYP2D6 67/4885USP2 4085/4885 |
| US-20090240051-A1 | New process for the production of oxabispidines | AVPR1B, CCNB1, QDPR | TSHR 1299/4885CYP2D6 14/4885USP2 4240/4885 |
| US-20090036675-A1 | New process for production of oxabispidines | AVPR1B, CCNB1, DHPS | TSHR 1215/4885CYP2D6 14/4885USP2 4326/4885 |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | TSHR 1242/4885CYP2D6 93/4885USP2 4320/4885 |
| US-20090062532-A1 | Chemical Intermediate | NAT1, CYP2B6, CBR1 | TSHR 1686/4885CYP2D6 44/4885USP2 3954/4885 |
| US-20100160626-A1 | Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes | CYP2D6, KCNH1, CYP2B6 | TSHR 2116/4885CYP2D6 1/4885USP2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.